Epidarex Capital
William Burns has over 40 years of leadership in the Pharmaceutical industry with extensive experience in international R&D, commercial, business development and operations.
He served for 23 years in senior positions at Swiss global healthcare company F.Hoffman La Roche (Roche), most recently as Chief Executive Officer of Roche Pharmaceuticals. William Burns had significant involvement in the privatization of Genentech, the integration of Boehringer Mannheim and the negotiations that resulted in Roche becoming a majority owner of Chugai in Japan.
Current key appointments include: Vice Chairman of Vestergaard Frandsen (Switzerland); Vice Chairman of Mesoblast (Australia); Member of the Advisory Group of Novo A/S (Denmark); Member of the Advisory Board for BioMed Partners (Basel) and member of the International Advisory Council of Chugai, Japan.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Epidarex Capital
Epidarex Capital is a leading transatlantic venture capital firm that invests in early-stage, high growth life science opportunities in under-ventured markets. Epidarex funds ground-breaking research, often building companies from scratch, to address large unmet medical needs with solutions that provide significant benefits to patients.